Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Haw ParHAWPF 93 Cyclically Adjusted PS Ratio is 14.12 as of Jul. 15, 2026, which is 4% above its 10-year median of 13.59. GuruFocus rates HAWPF with a GF Score™ of 93/100 and a GF Value™ of $8.51. The stock has 8 warning signs investors should review. Among 752 Drug Manufacturers companies, Haw Par ranks worse than 95.21% on this metric.
The historical rank and industry rank for Haw Par's Cyclically Adjusted PS Ratio or its related term are showing as below:
HAWPF'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 9.32 Med: 13.59 Max: 18.33
Current: 15.33
During the past 13 years, Haw Par's highest Cyclically Adjusted PS Ratio was 18.33. The lowest was 9.32. And the median was 13.59.
HAWPF's Cyclically Adjusted PS Ratio is ranked worse than 95.21% of 752
companies
in the Drug Manufacturers industry
Industry Median: 1.99
vs HAWPF: 15.33
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Haw Par's adjusted revenue per share data of for the fiscal year that ended in Dec25 was $0.805. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.85 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Haw Par (OTCPK:HAWPF) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Haw Par Cyclically Adjusted PS Ratio Related Terms
Haw Par Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Haw Par's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAWPF vs LLY, JNJ, ABBV: Cyclically Adjusted PS Ratio Comparison
For the Drug Manufacturers - General subindustry, Haw Par's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haw Par Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Haw Par's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Haw Par's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Haw Par's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 14.12 mean?
Haw Par (HAWPF) has a Cyclically Adjusted PS Ratio of 14.12 as of Jul. 15, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Haw Par and its competitors. This is near median its historical median of 13.59. Over the past decade, Haw Par's Cyclically Adjusted PS Ratio has ranged from 9.32 to 18.33. According to the industry distribution chart, Haw Par ranks #716 out of 752 companies in the Drug Manufacturers industry, placing it in the top 95.2%.
Is Haw Par's Cyclically Adjusted PS Ratio too high?
Haw Par's current Cyclically Adjusted PS Ratio of 14.12 is near median its 10-year median of 13.59. Over the past 10 years, this metric has ranged from a low of 9.32 to a high of 18.33. The Drug Manufacturers industry median Cyclically Adjusted PS Ratio is 1.99. Haw Par's value of 14.12 is 609.5% above this industry median. Based on the distribution chart, Haw Par ranks #716 out of 752 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Haw Par has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Haw Par's Cyclically Adjusted PS Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Haw Par ranks #716 out of 752 companies for Cyclically Adjusted PS Ratio. This places Haw Par in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 1.99. Haw Par's value of 14.12 is 609.5% above this benchmark. Historically, Haw Par's own Cyclically Adjusted PS Ratio has ranged from 9.32 to 18.33 over the past decade. While the company's 10-year median is 13.59 vs. the industry median of 1.99, Haw Par has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Drug Manufacturers company?
The median Cyclically Adjusted PS Ratio among Drug Manufacturers companies is 1.99, based on 752 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haw Par's current Cyclically Adjusted PS Ratio of 14.12 is 609.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Haw Par and its competitors. For the Drug Manufacturers industry, the median Cyclically Adjusted PS Ratio is 1.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haw Par's current Cyclically Adjusted PS Ratio is 14.12, which is near median its own 10-year median of 13.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haw Par stock overvalued right now?
Haw Par (HAWPF) has a current Cyclically Adjusted PS Ratio of 14.12. The stock's GF Value™ is $8.51, compared to a current price of $12.00 — trading 41% above its estimated fair value. The current Cyclically Adjusted PS Ratio is 14.12, which is near median its 10-year median of 13.59 and 609.5% above the Drug Manufacturers industry median of 1.99. Haw Par's overall GF Score™ is 93/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Haw Par (HAWPF), the current Cyclically Adjusted PS Ratio is 14.12 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haw Par (HAWPF) Overvalued in 2026?
Based on GuruFocus' analysis, Haw Par stock appears to be overvalued.
The current stock price of $12.00 is trading 41% above its estimated GF Value™ of $8.51.
Key valuation signals for HAWPF:
Cyclically Adjusted PS Ratio: 14.12 (near median its 10-year median of 13.59)
GF Value™: $8.51 vs. price of $12.00 (41% above fair value)
Industry Position: 609.5% above the Drug Manufacturers median (#716 of 752)
No single metric tells the full story. See the HAWPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haw Par Corp Ltd is a drug manufacturing company that operates multiple brands. The company is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, Property segment, and Leisure segment. The company generates the majority of its revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands. Geographically, it generates key revenue from the other ASEAN and other Asian countries.
93GF Score
Get the complete analysis for HAWPF
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAWPF has been successfully added to your 
